-+ 0.00%
-+ 0.00%
-+ 0.00%

Aligos licenses pevifoscorvir sodium China rights to Amoytop for USD 25 million upfront

PUBT·04/21/2026 20:34:02
Listen to the news
Aligos licenses pevifoscorvir sodium China rights to Amoytop for USD 25 million upfront
  • Aligos entered license deal on April 16, 2026 granting Amoytop exclusive rights to develop, manufacture, and commercialize pevifoscorvir sodium for HBV, including HBV-HDV co-infection, in mainland China, Taiwan, Hong Kong, and Macau.
  • Agreement calls for USD 25 million upfront payment to Aligos.
  • Aligos is eligible for up to USD 420 million in development, regulatory, and commercial milestones.
  • Deal includes tiered high single-digit royalties on net sales in territory.
  • License becomes effective upon Amoytop shareholder approval expected within 30 days, with automatic termination if approval is not received within 45 days of signing.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aligos Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-166987), on April 21, 2026, and is solely responsible for the information contained therein.